Two Patients Treated with CRISPRed Cells in Immunotherapy Trial
Two Patients Treated with CRISPRed Cells in Immunotherapy Trial
One person with multiple myeloma and one with sarcoma are the first so far to receive the genetically engineered T cells in the study.
Two Patients Treated with CRISPRed Cells in Immunotherapy Trial
Two Patients Treated with CRISPRed Cells in Immunotherapy Trial

One person with multiple myeloma and one with sarcoma are the first so far to receive the genetically engineered T cells in the study.

One person with multiple myeloma and one with sarcoma are the first so far to receive the genetically engineered T cells in the study.

immunotherapy
Tuberculosis Can Emerge After Cancer Immunotherapy
Tuberculosis Can Emerge After Cancer Immunotherapy
Ashley Yeager | Apr 1, 2019
At least a handful of patients have developed active TB after receiving cancer treatment designed to boost the immune system’s antitumor response.
Cancer Vaxxer: A Profile of Miriam Merad
Cancer Vaxxer: A Profile of Miriam Merad
Anna Azvolinsky | Apr 1, 2019
The Mount Sinai oncologist studies innate immune cells with the goal of designing novel immunotherapies, including cancer vaccines.
Contending with Resistance in Cancer Immunotherapy
Contending with Resistance in Cancer Immunotherapy
Marissa Fessenden | Apr 1, 2019
Researchers describe ways to study how cancer cells evade therapies that harness the immune system.
Miracle Elixirs
Miracle Elixirs
Bob Grant | Apr 1, 2019
A long way into the quest to vanquish cancer, our ears strain to hear the words, “Cancer is cured”—a yearning that can cloud our judgment.
The Next Frontier of CAR T-Cell Therapy: Solid Tumors
The Next Frontier of CAR T-Cell Therapy: Solid Tumors
Kerry Grens | Apr 1, 2019
The technology has wowed the field by all but obliterating some patients’ blood cancers, but solid malignancies present new challenges.
Infographic: CAR-T Cells in Solid Versus Liquid Cancers
Infographic: CAR-T Cells in Solid Versus Liquid Cancers
Kerry Grens | Apr 1, 2019
Tumor accessibility, heterogeneity, and microenvironment vary between the two classes of malignancies.
<em>Nature&nbsp;</em>Retracts Paper on Delivery System for CAR T Immunotherapy
Nature Retracts Paper on Delivery System for CAR T Immunotherapy
Diana Kwon | Feb 20, 2019
The manuscript had amassed more than 50 comments about problematic figures and data on PubPeer.
More Cancer Mutations, Better Immunotherapy Outcomes
More Cancer Mutations, Better Immunotherapy Outcomes
Catherine Offord | Jan 15, 2019
Immune checkpoint inhibitors are generally most effective against tumors with more genetic mutations, according to a new study, although the relationship isn’t true for all cancers.
Bristol-Myers Squibb to Buy Celgene for $74 Billion
Bristol-Myers Squibb to Buy Celgene for $74 Billion
Catherine Offord | Jan 3, 2019
The deal between the two biopharmaceutical giants will boost the purchaser’s cancer drug portfolio.